The treatment for metastatic renal cell carcinoma (RCC) has changed dramatically after the beginning of molecular-targeted therapies. However, the treatment for liver metastasis is still difficult in patients with metastatic RCC. We treated liver metastases (8 target lesions) of RCC with stylene-maleic acid neocarzinostatin (SMANCS)/Lipiodol therapy. At the treatment procedure, a catheter was inserted at the femoral artery (Seldinger's method), a microcatheter was selectively inserted into the branch of hepatic artery which fed the liver metastasis, and then SMANCS/Lipodol was infused. We treated 1, 2 and 1 patient 4, 2, and 1 time, respectively. One lesion treated with SMANCS/Lipodol was further treated by radiofrequency ablation 13 days later. Of 6 metastatic lesions which could be followed up for more than 6 months after the treatment, one had partial response for 4 months and 4 had stable disease for more than 6 months. Four of the 6 lesions shrunk after SMANCS/Lipiodol treatment. Two of 4 patients survived more than 18 months after the first SMANCS/Lipiodol therapy. In all 9 SMANCS/Lipiodol treatments, grade 1 liver dysfunction (44.4%), ascites (11.1%) and fatigue (11.1%) occurred after the treatments. These adverse events were all improved by conservative treatments. SMANCS/Lipiodol therapy can be a treatment option as local treatment for liver metastasis of RCC.
|Number of pages||7|
|Journal||Acta Urologica Japonica|
|Publication status||Published - 10-2010|
All Science Journal Classification (ASJC) codes